Stocktoria
Verrica Pharmaceuticals Inc. VRCA
Verrica Pharmaceuticals Inc. statistics & valuation
Market cap$103.1M
P / S2.9×
P / B4.2×
Net margin-50.3%
Return on equity-72.3%
FCF margin-49.5%
Net cash$30.1M
Enterprise value USD$72.9M
Earnings yield EBIT/EV-16.7%
Return on capital-39.7%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -34.2% | -871.3% | -1283.4% | -235.8% | -257.6% | — | — | — | — |
| Net margin | -50.3% | -1012.1% | -1307.5% | -271.1% | -292.3% | — | — | — | — |
| FCF margin | -49.5% | -805.6% | -759.9% | -209.8% | -237.2% | — | — | — | — |
| Return on assets | -37.9% | -141.5% | -82.1% | -54.8% | -43.8% | -57.6% | -41.2% | -22.5% | -49.1% |
| Return on equity | -72.3% | 776.7% | -339.0% | -61.2% | -107.6% | -129.4% | -43.4% | -23.1% | 63.3% |
| Debt / equity | 0.00× | -3.14× | 2.17× | 0.00× | — | — | — | — | — |
| Current ratio | 2.59 | 1.76 | 4.55 | 11.31 | 1.61 | 1.71 | 19.39 | 36.80 | 14.75 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.